{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:33:31Z","timestamp":1773945211043,"version":"3.50.1"},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.20201166","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T12:44:44Z","timestamp":1631882684000},"page":"713-717","source":"Crossref","is-referenced-by-count":4,"title":["The effect of Mirabegron and Duloxetine combination in mixed-type urinary incontinence treatment"],"prefix":"10.1590","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-2856","authenticated-orcid":false,"given":"Ahmet","family":"Ariman","sequence":"first","affiliation":[{"name":"Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6325-3297","authenticated-orcid":false,"given":"Erkan","family":"Merder","sequence":"additional","affiliation":[{"name":"Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-2293","authenticated-orcid":false,"given":"Mehmet G\u00f6khan","family":"\u00c7ulha","sequence":"additional","affiliation":[{"name":"Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2021,6]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen BT","year":"2010","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","article-title":"Global prevalence and economic burden of urgency urinary incontinence: a systematic review","volume":"65","author":"Milson I","year":"2014","journal-title":"Eur Urol"},{"key":"ref3","series-title":"WHO ageing and life course","year":"2014"},{"key":"ref4","series-title":"Incontinence: 5th International Consultation on Incontinence","first-page":"15","volume-title":"Epidemiology of urinary incontinence (UI) and other Lower Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse (POP) and Anal Incontinence (AI)","author":"Milsom I","year":"2013"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1464-410X.2012.11652.x","article-title":"Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder?","volume":"112","author":"Giarents I","year":"2013","journal-title":"BJU Int"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20870","article-title":"Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence","volume":"29","author":"Abrams P","year":"2010","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.ju.0000162020.10447.31","article-title":"The effect of fluid intake on urinary symptoms in women","volume":"174","author":"Swithinbank L","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eururo.2006.08.041","article-title":"Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence a systematic review","volume":"51","author":"Mariappan P","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti VW","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial","volume":"63","author":"Khullar V","year":"2013","journal-title":"Eur Urol"},{"key":"ref11","series-title":"Urinary incontinence in women: management. Clinical guideline [CG171]"},{"key":"ref12","series-title":"Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness","author":"Shamliyan T","year":"2012"},{"issue":"1","key":"ref13","first-page":"CD005654","article-title":"Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women","author":"Dumoulin C","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","series-title":"Incontinence: 5th International Consultation on Incontinence","first-page":"1101","volume-title":"Adult conservative management","author":"Bradley C","year":"2013"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/nau.20471","article-title":"Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence","volume":"27","author":"Bent AE","year":"2008","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-156-12-201206190-00436","article-title":"Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review","volume":"156","author":"Shamliyan T","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"ref17","first-page":"CD001405","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","author":"Cody JD","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng LH","year":"2009","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple CR","year":"2008","journal-title":"Eur Urol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.juro.2013.10.046","article-title":"Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review","volume":"191","author":"Veenboer PW","year":"2014","journal-title":"J Urol"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner JS","year":"2010","journal-title":"BJU Int"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.urology.2004.02.029","article-title":"Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial","volume":"64","author":"Khullar V","year":"2004","journal-title":"Urology"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00192-005-0023-4","article-title":"Solifenacine: as effective in mixed urinary incontinence as in urge urinary incontinence","volume":"17","author":"Kelleher C","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple CR","year":"2013","journal-title":"Eur Urol"},{"issue":"9-10","key":"ref25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5489\/cuaj.3098","article-title":"Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada","volume":"9","author":"Wagg A","year":"2015","journal-title":"Can Urol Assoc J"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T12:45:10Z","timestamp":1631882710000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302021000600713&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["S0104-42302021000600713"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20201166","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}